Sharemaestro company-news research for AbbVie Inc. (ABBV), showing current tone, evidence confidence, direct company coverage, sector and industry context, completed price response and the source headlines used on the page. Scores describe published news evidence. Confidence describes the amount, freshness, source breadth and direct company relevance of that evidence. Price context is shown separately.
MEX
Mexico
Measured evidence
Company news sentiment
ABBV news sentiment
AbbVie Inc.
Company headlines compared by relevance, subject, source independence, tone and the market's completed price response.
Weighted tone60Neutral is 50
Constructive news tone
70/100 evidence confidence
100% direct company focus
7 current stories across 1 publishers
Current company news
Positive news being faded
Constructive news tone is drawn from 7 fresh independent stories, including 7 company-specific items across 1 publishers.
Latest source headline AbbVie (ABBV) Wins Canada Reimbursement Backing For Adult Migraine Treatment finance.yahoo.com · 11 Aug 2026 22:15What supports the read
7 current stories are mapped specifically to ABBV.
Cross-story agreement is 82/100, indicating a comparatively coherent tape.
What tempers the read
Only 1 publisher currently contribute to the measured read.
Constructive headlines are not being rewarded by price, which raises a rejection flag.
60/100
Weighted toneConstructive news tone
70/100
Evidence confidencesolid confidence
100%/100
Company focus7 direct stories
82/100
Evidence agreement18/100 dispersion
News history
Tone and story flow over 21 days
24 Jul03 Aug13 Aug
Weighted toneStory volumeNeutral 50
Evidence confidence
What supports the score
Confidence rises through sample depth, independent publishers, direct company relevance, freshness and agreement. A high or low tone score is not itself evidence of reliability.
Sample depth78
6.2 effective storiesSource breadth20
1 independent publishersDirect relevance100
company-specific evidence shareFreshness72
recency-weighted evidenceAgreement82
cross-story consistencySource independence0
lower publisher concentrationPrice context
Sentiment against the 26-week price path
Constructive headlines are not being rewarded by price, which raises a rejection flag.
13 Feb15 May07 Aug
Weekly close, indexedSentiment score
Sentiment confirms active trend
News subjects
What is shaping the score
Earnings675 stories · 71%
Deals and strategy311 stories · 14%
Market update621 stories · 14%
Source mix
Where the evidence comes from
finance.yahoo.com647 stories · 100%
Recurring subjects
Subjects appearing most often
Earnings5Biotech5Pharma3Fda Approval3Share Price2Guidance2Balance Sheet2Shareholder1Revenue Growth1Quarterly Results1
Earlier readings
How the score has changed
ConstructiveBalanced or withheldCautious
Source headlines
The news behind the score
Every row shows the public evidence used to understand the read. Direct company stories carry more weight than industry or sector context; duplicate coverage is consolidated before scoring.
#165Tone
finance.yahoo.comDirect company coverage
AbbVie (ABBV) Wins Canada Reimbursement Backing For Adult Migraine Treatment
Find your next quality investment with Simply Wall St's easy and powerful screener, trusted by over 7 million individual investors worldwide. AbbVie (NYSE: ABBV) received a recommendation from Canada's Drug Agency to reimburse UBRELVY for the acute treatment of migraine in adults. The decision follows Phase 3 trial results and a review process that included direct input from patients and clinicians. The recommendation expands access to UBRELVY in Canada and broadens AbbVie's neuroscience portfolio in migraine care. For more ideas in this area, take a look at 43 healthcare AI stocks.NYSE:ABBV E
BiotechCanada ReimbursementMigraine CareNeuroscienceQuarterly Results
- Published
- 11 Aug 2026 22:15
- Catalyst
- Earnings
- Evidence role
- Direct company coverage
- Duplicates
- 1 consolidated
#244Tone
finance.yahoo.comDirect company coverage
AbbVie (ABBV) Gains On Botox Filing, Is The 9% Discount Still There?
Make better investment decisions with Simply Wall St's easy, visual tools that give you a competitive edge. AbbVie (ABBV) is back in focus after Allergan Aesthetics reported that the FDA accepted a supplemental Biologics License Application for Botox Cosmetic targeting masseter muscle prominence in adults, which would be a potential fifth U.S. aesthetic indication. See our latest analysis for AbbVie. Alongside Allergan Aesthetics' Botox update and several recent approvals and guidance changes, AbbVie's share price has moved to $247.97, with a 90 day share price return of 19.3% and a 1 year tot
BiotechEarningsFda ApprovalHealthcareShare PriceShareholder
- Published
- 11 Aug 2026 21:11
- Catalyst
- Earnings
- Evidence role
- Direct company coverage
- Duplicates
- 1 consolidated
#390Tone
finance.yahoo.comDirect company coverage
How Much Did Immunology Drugs Contribute to AbbVie's Q2 Performance?
AbbVie ABBV announced encouraging second-quarter 2026 results last month, which beat expectations for both earnings and sales. A significant portion of this growth came from the continued strength of its two blockbuster immunology medications, Skyrizi and Rinvoq, which together accounted for more than 47% of total revenues. Skyrizi sales jumped 24% year over year on an operational basis to $5.5 billion, while Rinvoq sales rose 23.7% to more than $2.5 billion. Both drugs benefited from strong demand and market-share gains across their approved indications, especially in the popular inflammatory
BiotechCompetitionEarningsFda ApprovalImmunology
- Published
- 11 Aug 2026 16:54
- Catalyst
- Earnings
- Evidence role
- Direct company coverage
- Duplicates
- 1 consolidated
#462Tone
finance.yahoo.comDirect company coverage
Allergan Aesthetics Refreshes Allergan Partner Privileges® to Better Support Today's Modern Aesthetics Practices
Updated program delivers simplified savings, greater benefits transparency, and expanded opportunities for practice growth Introduces new rewards opportunities for customer segments, including first-time APP members, growing practices, and long-standing loyal customers IRVINE, Calif., Aug. 11, 2026 /PRNewswire/ -- Allergan Aesthetics, an AbbVie company, today announced updates to Allergan Partner Privileges® (APP), its customer portfolio loyalty program, designed to better support the way today's aesthetics practices operate and grow. Shaped by customer feedback and market momentum, the progra
- Published
- 11 Aug 2026 12:00
- Catalyst
- Market update
- Evidence role
- Direct company coverage
- Duplicates
- 1 consolidated
#569Tone
finance.yahoo.comDirect company coverage
AbbVie’s (ABBV) Botox Just Got A Step Closer To A Fifth Use
AbbVie (NYSE:ABBV) just moved a step closer to expanding one of its most recognizable brands. On August 4, the FDA accepted for review a supplemental Biologics License Application for Botox Cosmetic to treat masseter muscle prominence, the jaw-muscle bulge that can give a face a wider, squarer look. If cleared, Botox Cosmetic would become the first and only neurotoxin approved for that use in the US and the fifth aesthetic indication for a drug that already anchors AbbVie's fastest-growing units.AbbVie's (ABBV) Botox Just Got A Step Closer To A Fifth Use Bull Case: A Pipeline That Keeps Findin
Balance SheetBiotechDebtEarningsFda ApprovalPharma
- Published
- 10 Aug 2026 16:59
- Catalyst
- Earnings
- Evidence role
- Direct company coverage
- Duplicates
- 1 consolidated
#688Tone
finance.yahoo.comDirect company coverage
The 5 Most Interesting Analyst Questions From AbbVie’s Q2 Earnings Call
The 5 Most Interesting Analyst Questions From AbbVie's Q2 Earnings Call AbbVie's second quarter results reflected robust product performance but were met with cautious investor sentiment. Management credited double-digit sales growth to strong execution in core immunology therapies, especially SKYRIZI and RINVOQ, and notable gains in the neuroscience portfolio. CEO Robert Michael emphasized that "each [portfolio] delivered growth above 20%," with SKYRIZI achieving market leadership in multiple countries. However, the quarter also saw persistent biosimilar pressure on legacy products and a comp
BiotechEarningsFree Cash FlowGuidancePharmaRevenue Growth
- Published
- 09 Aug 2026 23:33
- Catalyst
- Earnings
- Evidence role
- Direct company coverage
- Duplicates
- 1 consolidated
#731Tone
finance.yahoo.comDirect company coverage
AbbVie (ABBV) Is Down 5.3% After Raising 2026 Revenue Outlook and Issuing New Debt - What's Changed
In late July and early August 2026, AbbVie reported stronger second‑quarter results, raised full‑year revenue guidance to about US$67.6 billion, advanced RINVOQ and BOTOX regulatory milestones, and completed a multi‑billion‑dollar mix of new fixed‑ and floating‑rate bond issuances. Together, these moves highlight how AbbVie is simultaneously expanding its immunology, neuroscience and aesthetics franchises while tapping debt markets to support its pipeline and deals such as the planned Apogee Therapeutics acquisition. Next, we'll examine how AbbVie's raised revenue outlook, alongside its expand
Balance SheetBondsEarningsGuidancePharmaShare Price
- Published
- 07 Aug 2026 20:14
- Catalyst
- Deals and strategy
- Evidence role
- Direct company coverage
- Duplicates
- 1 consolidated
How the page works
How to read the score
It describes the weighted balance of qualifying headlines. A score of 50 can mean a balanced tape or that direction has been withheld for insufficient evidence; the status label distinguishes them.
Confidence measures depth, source breadth, direct relevance, freshness and agreement. It does not rise merely because the tone is extreme.
Weekly price response, trend and fair-value position test whether the market is accepting or rejecting the news. They never rewrite the news score.
The page describes completed evidence available at the stated time. It is research context, not a forecast, recommendation, target or execution instruction.